IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline

IGC Pharma, Inc.

Terry Lierman appointed as independent Class B director, effective March 12, 2024.
Lierman brings healthcare leadership: co-chair IHV, founder of Children's Research Institute, PanCAN, NOFAS.
Granted options to buy 150,000 shares at $0.30/share; 50,000 vest immediately, balance over 2025-2026.
His expertise will support Phase 2 trial of IGC-AD1 for agitation in Alzheimer's and preclinical TGR-63.
CEO Ram Mukunda cites Lierman's strategic guidance as pivotal for pipeline advancement.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Terry Lierman

independent Class B director

IGC · IGC Pharma, Inc.

Effective: 2024-03-12
Filed: March 13, 2024, 7:59 PM ET

On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Terry Lierman was appointed as independent Class B director at IGC Pharma, Inc..

Action: appointed
Role: independent Class B director

Exact text from the filing

On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.

View on SEC.gov

IGC Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-24-000233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.